Evidence map›Paper›PMID 18852491›Full record

ArticleOncology2008

Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Ayelet Shabtay, Hagar Sharabani, Zeev Barvish, Michael Kafka, Doron Amichay, Joseph Levy, Yoav Sharoni, Milan R Uskokovic, George P Studzinski, Michael Danilenko

Open access · greenAbstract read
In one paragraph

Article in Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Antioxidants (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Article
  6. Anticancer Activity ofNutrients · 2020
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. The Use of 1α,25-Dihydroxyvitamin D₃ as an Anticancer Agent.International journal of molecular sciences · 2016
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Ayelet ShabtayDepartment of Clinical Biochemistry, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Hagar Sharabani
Zeev Barvish
Michael Kafka
Doron Amichay
Joseph Levy
Yoav Sharoni
Milan R Uskokovic
George P Studzinski
Michael Danilenko
Ben-Gurion University of the Negev · ILPalmetto Hematology Oncology · USRutgers New Jersey Medical SchoolSoroka Medical Center · IL

Funding

Vitamin D Analogs as Adjuvants in Chemotherapy of CancerR01CA044722 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 1987 to 2016
$3.5M
VITAMIN D PLANT ANTIOXIDANT SILIBININ IN LEUKEMIA TRANSLATIONAL STUDYR01CA117942 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 2007 to 2010
$772k
NCI NIH HHS R01 CA044722NCI NIH HHS R01 CA117942NCI NIH HHS R01-CA117942-01NCI NIH HHS R01-CA 44722-18
6 · The paper itself

Abstract

objectiveDifferentiation therapy with the hormonal form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1,25D(3)), is a promising approach to treatment of acute myeloid leukemia (AML); however, 1,25D(3) induces hypercalcemia at pharmacologically active doses. We investigated the in vitro and in vivoantileukemic efficacy of combined treatment with non-toxic doses of a low-calcemic 1,25D(3) analogue, 1,25-dihydroxy-21(3-hydroxy-3-methyl-butyl)-19-nor-cholecalciferol (19-nor-Gemini; Ro27-5646), and rosemary plant agents in a mouse model of AML.

methodsProliferation and differentiation of WEHI-3B D- (WEHI) murine myelomonocytic leukemia cellsin vitro were determined by standard assays. Reactive oxygen species, glutathione and protein expression levels were measured by flow cytometry, enzymatic assay and Western blotting, respectively. Systemic AML was developed by intravenous injection of WEHI cells in syngeneic Balb/c mice.

results19-nor-Gemini had a higher potency than its parent compounds, Gemini (Ro27-2310) and 1,25D(3), in the induction of differentiation (EC(50) = 0.059 +/- 0.011, 0.275 +/- 0.093 and 0.652 +/- 0.085 nM, respectively) and growth arrest (IC(50) = 0.072 +/- 0.018, 0.165 +/- 0.061 and 0.895 +/- 0.144 nM, respectively) in WEHI cells in vitro, and lower in vivo toxicity. Combined treatment of leukemia-bearing mice with 19-nor-Gemini (injected intraperitoneally) and standardized rosemary extract (mixed with food) resulted in a synergistic increase in survival (from 42.2 +/- 2.5 days in untreated mice to 66.5 +/- 4.2 days, n = 3) and normalization of white blood cell and differential counts. This was consistent with strong cooperative antiproliferative and differentiation effects of low concentrations of 19-nor-Gemini or 1,25D(3) combined with rosemary extract or its major polyphenolic component, carnosic acid, as well as with the antioxidant action of rosemary agents and vitamin D derivatives in WEHI cell cultures.

conclusionCombined effectiveness of 1,25D(3) analogues and rosemary agents against mouse AML warrants further exploration of this therapeutic approach in translational models of human leukemia.

Indexed as

Disease Models, AnimalAbietanesAnimalsAntioxidantsBone MarrowCalcitriolCell DifferentiationCell ProliferationCholecalciferolDrug SynergismHumansImmunoblottingLeukemia, ExperimentalLeukemia, Myeloid, AcuteMiceMice, Inbred BALB C1,25-dihydroxy-16,23-diene vitamin D31,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)vitamin D(3)AbietanesAntioxidantsCalcitriolCholecalciferolPlant ExtractsReactive Oxygen Speciessalvin

Identifiers

PMID18852491
PMCPMC2826875
OpenAlexW2007160987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.